PNEUMOVAX 23 is a vaccine indicated for active immunization for the prevention of pneumococcal disease caused by the 23 serotypes contained in the vaccine (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F).

Pharmacies offer an important opportunity to increase pneumococcal vaccination rates for eligible adults

Patients ages ≥65, as well as those with diabetes, chronic heart disease, or COPD, are at increased risk for invasive pneumococcal disease (IPD).1,2 Yet, despite CDC recommendations to administer PNEUMOVAX 23 to these patients, vaccination rates remain low.3,4

Pharmacies present a unique opportunity to raise awareness of the increased risk of pneumococcal disease and to recommend appropriate patients receive their CDC-recommended routine dose of PNEUMOVAX 23.5

Risk and vaccination
rates for adults ages ≥65

Adults ages ≥65 years are at increased risk for IPD*,1,a

More than half of these adults had not received PNEUMOVAX 23, according to a CDC retrospective analysis published in 20173,b

~3X
RISK*
65 YEARS
OR OLDER
~43% VACCINATION RATE

*Versus healthy adults aged 18-641,a

Risk and vaccination rates for adults ages 19-64 with certain chronic conditions

Adults ages 19-64 with these chronic conditions are at increased risk for IPD✝,2,c

Pneumococcal vaccination rates for these adults remained low 5 years after initial diagnosis, according to a seperate study from 20164,d

~3X
RISK
DIABETES
MELLITUS
~21% VACCINATION RATE
~3X
RISK
CHRONIC
HEART DISEASE
~13% VACCINATION RATE
~7X
RISK
CHRONIC LUNG
DISEASE (COPD)
~17% VACCINATION RATE

Versus healthy adults of the same age2,c

aStudy Design: Retrospective cohort study using data from January 1, 2006, through December 31, 2010, from 3 health care claims databases representing >35 million insured adults ≥18 years of age. Risk for IPD was compared between healthy adults ≥65 years of age and healthy adults 18 to 64 years of age.1

bStudy Design: As a proxy for estimating PNEUMOVAX 23 vaccination coverage among adults ≥65 years before and after implementation of the CDC 2014 pneumococcal vaccine recommendations, the CDC analyzed pneumococcal vaccination claims submitted for reimbursement to the Centers for Medicare and Medicaid Services among Medicare Part A and B beneficiaries aged ≥65 years from September 19, 2009, through September 18, 2017. Claims for PNEUMOVAX 23 from hospitals and outpatient settings were identified by the use of Current Procedural Terminology (CPT) codes. Claims submitted for at least one dose of PCV13 (regardless of PNEUMOVAX 23 status), at least one dose of PNEUMOVAX 23 (regardless of PCV13 status), at least one dose of each PCV13 and PNEUMOVAX 23, and at least one dose of either vaccine were included and stratified by age, race/ethnicity, state, and the presence of chronic or immunocompromising conditions for which PCV13, PNEUMOVAX 23, or both vaccines are indicated among adults aged <65 years.3

cStudy Design: Retrospective cohort study (adults aged ≥18 years) using data from January 1, 2006, through December 31, 2010, from 3 health care claims databases representing >35 million insured adults. Risk for IPD was compared to age-matched healthy counterparts.2

dStudy Design: A 2016 retrospective cohort study of 552,942 adults aged 19 to 64 years diagnosed with at least one new chronic medical condition from 2009 to 2013 was conducted using the Truven Health MarketScan® Commercial Claims and Encounters database to assess pneumococcal vaccination status. After diagnosis, the follow-up period ranged from 1 to 6 years. Chronic conditions were identified using ICD-9-CM diagnosis codes; date of diagnosis was determined by the first ICD code recorded. Pneumococcal vaccination was identified using Current Procedural Terminology (CPT) codes and National Drug Code (NDC) numbers for pharmacy claims.4

CDC, Centers for Disease Control and Prevention; COPD, chronic obstructive pulmonary disease; PCV13, 13-valent pneumococcal conjugate vaccine.

CPT is a registered trademark of the American Medical Association.

ref1

Reference

  1. Weycker D, Farkouh RA, Stratton DR, et al. Rates and costs of invasive pneumococcal disease and pneumonia in persons with underlying medical conditions. BMC Health Serv Res. 2016;16:182.

ref2

Reference

  1. Shea KM, Edelsberg J, Weycker D, et al. Rates of pneumococcal disease in adults with chronic medical conditions. Open Forum Infect Dis. 2014;1(1):1–9.
ref3

Reference

  1. Centers for Disease Control and Prevention (CDC). Adult vax view. Pneumococcal vaccination among US Medicare beneficiaries aged ≥65 years, 2009-2017. Accessed January 20, 2021. https://www.cdc.gov/vaccines/imz-managers/coverage/adultvaxview/pubs-resources/pcv13-medicare-beneficiaries.html
ref4

Reference

  1. Petigara T, Zhang D. Pneumococcal vaccine coverage in adults aged 19-64 years, newly diagnosed with chronic conditions in the U.S. Am J Prev Med. 2018;54(5):630–636. doi:10.1016/j.amepre.2018.01.033.
ref5

Reference

  1. Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: Updated recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 2019;68(46):1069–1075.

Indication for PNEUMOVAX 23

PNEUMOVAX® 23 (Pneumococcal Vaccine Polyvalent) is a vaccine indicated for active immunization for the prevention of pneumococcal disease caused by the 23 serotypes contained in the vaccine (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F).

PNEUMOVAX 23 is approved for use in persons 50 years of age or older and persons aged ≥2 years who are at increased risk for pneumococcal disease.

PNEUMOVAX 23 will not prevent disease caused by capsular types of pneumococcus other than those contained in the vaccine.

Do not administer PNEUMOVAX 23 to individuals with a history of a hypersensitivity reaction to any component of the vaccine.
Defer vaccination with PNEUMOVAX 23 in persons with moderate or severe acute illness.

Do not administer PNEUMOVAX® 23 (Pneumococcal Vaccine Polyvalent) to individuals with a history of a hypersensitivity reaction to any component of the vaccine.

Defer vaccination with PNEUMOVAX 23 in persons with moderate or severe acute illness.

Use caution and appropriate care in administering PNEUMOVAX 23 to individuals with severely compromised cardiovascular and/or pulmonary function in whom a systemic reaction would pose a significant risk.

Available human data from clinical trials of PNEUMOVAX 23 in pregnancy have not established the presence or absence of a vaccine-associated risk.

Since elderly individuals may not tolerate medical interventions as well as younger individuals, a higher frequency and/or a greater severity of reactions in some older individuals cannot be ruled out.

Persons who are immunocompromised, including persons receiving immunosuppressive therapy, may have a diminished immune response to PNEUMOVAX 23.

PNEUMOVAX 23 may not be effective in preventing pneumococcal meningitis in patients who have chronic cerebrospinal fluid (CSF) leakage resulting from congenital lesions, skull fractures, or neurosurgical procedures.

The most common adverse reactions, reported in >10% of subjects vaccinated with PNEUMOVAX 23 for the first time in a clinical trial, were: injection-site pain/soreness/tenderness, injection-site swelling/induration, headache, injection-site erythema, asthenia and fatigue, and myalgia.

For subjects aged 65 years or older in a clinical study, systemic adverse reactions which were determined by the investigator to be vaccine-related were higher following revaccination than following initial vaccination.

Vaccination with PNEUMOVAX 23 may not offer 100% protection from pneumococcal infection.

Before administering PNEUMOVAX 23, please read the accompanying Prescribing Information. The Patient Information also is available.

PNEUMOVAX® 23 (Pneumococcal Vaccine Polyvalent) is a vaccine indicated for active immunization for the prevention of pneumococcal disease caused by the 23 serotypes contained in the vaccine (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F).

PNEUMOVAX 23 is approved for use in persons 50 years of age or older and persons aged ≥2 years who are at increased risk for pneumococcal disease.

PNEUMOVAX 23 will not prevent disease caused by capsular types of pneumococcus other than those contained in the vaccine.

vaxRef

You are about to leave MerckVaccines.com

Vaxelis

Thank you for visiting.


US-PNX-01991 03/21